Article
Irvine, CA-IntraLase Corp. glided into the public realm in early October with a successful initial public offering (IPO) at the top of its indicated range, selling nearly 7.3 million shares and raising $86.6 million.
US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
FDA approves expanded label for fluocinolone acetonide intravitreal implant
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE